Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome696
Hybrid EASL Congress 2023516
Zolbetuximab treatment in metastatic gastric cancer478
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity478
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection460
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis403
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology388
Digestive Disease Week 2022363
Mapping neuroimmune interactions in the gut347
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa321
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed318
2023 FDA approvals in gastroenterology and hepatology315
Nomenclature of HBV core protein-targeting antivirals304
Black–White disparities across the colorectal cancer care continuum in the USA300
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis286
Artificial intelligence and automation in endoscopy and surgery275
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection235
Leveraging diet to engineer the gut microbiome220
Western lifestyle, metaflammation and the cell of origin of colon cancer213
Hepatic IRF3 in glucose intolerance205
Oral microbiome therapy efficacious for recurrent C. difficile infection193
Wound healing in the colon186
GWAS reveals variants for alcohol-related hepatocellular carcinoma182
Decoding therapy resistance in liver tumours: a giant leap181
A deep dive into the submerged ‘coeliac iceberg’179
New understanding of hepatobiliary MRI177
Lessons from incretin-based therapy in MASH and obesity172
Metastatic pancreatic cancer and the liver168
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract167
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges162
A crucial Fusobacterium nucleatum clade in colorectal cancer157
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation156
Bacteriophages and their potential for treatment of gastrointestinal diseases155
The global burden of coeliac disease: opportunities and challenges153
Inflammatory bowel disease in pregnancy and breastfeeding147
Integrated systems approach to identify environmental factors in intestinal inflammation144
Hepatocyte-derived biomarkers in alcohol-related cirrhosis142
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases138
Medical therapy of paediatric inflammatory bowel disease128
Lanifibranor and NASH resolution127
Implications of the evolving knowledge of the genetic architecture of MASLD126
Estimating dietary intake from human stool DNA124
Preventing the progression of cirrhosis to decompensation and death121
Characterizing the genomic landscape of colorectal cancer116
SSRIs and depression: role of gut–brain communication113
Probiotics for preterms: sharing complex decision-making108
HDCA ameliorates NAFLD in mice108
Metabolic diseases in the East Asian populations106
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook106
Human intestinal B cells in inflammatory diseases105
Liver, ageing and disease105
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management105
Current and future colorectal cancer screening strategies105
The path to successful hepatitis C elimination in Spain103
ECCO’24100
Author Correction: Hepatic immune regulation and sex disparities99
NAFLD prevalence in older patients with T2DM98
Phase III results for first-line treatment for metastatic colorectal cancer96
Microbiota and colorectal cancer — controlling for confounders challenges associations95
Gut microbiome and autism spectrum disorder94
Enteric nervous system transfers stress to the gut93
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’92
GLP1R agonists in NAFLD: a promising therapy on the horizon92
Transforming the landscape of liver cancer detection and care91
Artificial intelligence in liver cancer — new tools for research and patient management88
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance87
Hepatic glucose metabolism in the steatotic liver86
Neutrophils as potential therapeutic targets in hepatocellular carcinoma84
Foundations of gastrointestinal-based drug delivery and future developments80
Hepatic inflammatory responses in liver fibrosis79
SMART cancer risk prediction78
Immunoregulatory role of enteric glia78
Liver dialysis in ACLF76
AI predicts pancreatic cancer risk75
The gut microbiome in feast and famine74
0.075856924057007